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Hepatitis delta virus (HDV) is a sub-viral agent that is dependent for its life cycle on hepatitis B virus (HBV). The help it obtains from HBV is
limited to the sharing of envelope proteins. These proteins are needed to facilitate the assembly of the HDV genome into new virus particles, and
in turn, to allow the attachment and entry of HDV into new host cells. In other respects, the replication of the small single-stranded circular RNA
genome of HDV is independent of HBV. HDV genome replication produces two forms of a RNA-binding protein known as the long and small
delta antigens (Ag). All other proteins needed for HDV genome replication, especially the RNA-directed RNA polymerase activity, are provided
by the host cell. This mini-review article is a mixture of personal perspective and speculations about the future of HDV research. It starts with a
brief overview of HDV and its replication, notes some of the major unresolved questions, and directs the interested reader to more detailed
reviews.
D 2005 Elsevier Inc. All rights reserved.
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HDV was discovered in 1977 among a group of Italian
patients chronically infected with HBV, who developed serious
episodes of acute liver disease (Rizzetto et al., 1977). By 1980,
it was shown that HDV was an infectious agent responsible for
exacerbation of liver disease in these patients (Rizzetto et al.,
1980a). Both HBV and HDV are blood-borne infections. If a0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2005.09.033
* Fax: +1 215 728 3105.
E-mail address: john.taylor@fccc.edu.naive individual receives both viruses, it is referred to as a co-
infection. Alternatively, HDV infection of an individual already
chronically infected with HBV is referred to as a super-
infection (Farci, 2003). Worldwide, above 460 million people
are chronically infected with HBV and of these, it is speculated
that around 20 million also have chronic HDV (Radjef et al.,
2004). Acute HDV super-infections have a much greater risk of
evolving into a fulminating hepatitis with liver failure than
HBV alone. Chronic HDV infections are associated with more
rapidly progressing liver damage than patients infected with
HBV alone (Farci, 2003).06) 71 – 76
www.e
J.M. Taylor / Virology 344 (2006) 71–7672Epidemiologic studies of HDV show that it is present in
many different countries. Nucleotide sequence analyses of such
isolates has allowed sub-classification into what was initially
just three genotypes and more recently into a total of seven
genotypes (Radjef et al., 2004).
Vaccination against HBV will also protect against HDV.
Treatment of chronic HDV infections is currently limited to
extensive alpha-interferon therapy or in extreme situations, to
liver transplantation (Farci, 2003). Treatment with antivirals,
such as lamivudine, that are known to reduce HBV titers, have
not been successful in reducing HDV titers (Hoofnagle, 1998).
In mouse model systems (as also discussed later), isopre-
nylation inhibitors have been shown to transiently reduce
assembly of HDV (Bordier et al., 2002) but it is not yet
foreseeable that this kind of strategy will be used in patients
because of potential toxicity (Taylor, 2003). Ribavirin, which
in combination with interferon is the major antiviral therapy for
chronic hepatitis C virus infections, has not been effective for
treatment of HDV infections. This is puzzling since ribavirin
will block HDV genome replication in cell culture (Choi et al.,
1989; Rasshofer et al., 1991).
Experimental models and pathogenicity
HDV infection and replication can be achieved experimen-
tally in the chimpanzee using HBVas the helper virus (Rizzetto
et al., 1980b). Also, if the helper virus is replaced by
woodchuck hepatitis B virus (WHV), replication can also be
achieved in the Eastern woodchuck (Ponzetto et al., 1984). In
mice that have been transplanted with human hepatocytes,
HDV replication can also be achieved (Ohashi et al., 2000). If
mice transgenic for HBV sequences are injected with HDV,
HDV genome replication and assembly of new virus particles
will take place, but virus spread does not occur (Bordier et al.,
2003). Finally, if normal mice are injected with HDV, a limited
amount of infection in the liver takes place, but again, there is
no viral spread (Netter et al., 1993).
Since the genome of HDV can replicate in animal cells
independent of HBV, it is not surprising that many such
experimental systems are possible. Apparently without excep-
tion, transfection of mammalian cells with HDV cDNA will
lead to RNA-directed genome replication. In contrast, trans-
fection with HDV RNA, either natural genomic RNA or in
vitro transcribed genomic or antigenomic RNAs, will not
initiate replication. However, this blockage can be overcome in
several different ways: If the HDV RNA is co-transfected with
yAg (Dingle et al., 1998), or mRNA for yAg (Modahl and Lai,
1998) or if the recipient cell is already expressing yAg (Glenn
et al., 1990), HDV genome replication will take place.
In all of the above experimental systems, HDV genome
replication gradually declines due to the appearance with time
of altered forms of yAg that either do not support replication or
worse, act as dominant negative inhibitors of replication. The
most obvious example of this, as discussed in a later section, is
the larger form of yAg that arises because of a specific RNA-
editing event. Other forms of yAg can also arise due to
inappropriate RNA-editing and also via mis-incorporationduring RNA-directed RNA synthesis. To obviate such self-
limiting replication, a recent study described a new experi-
mental system (Chang et al., 2005a). A cell line was made to
conditionally express (under tetracycline control) a genetically
stable form of the essential small yAg. These cells were
transfected with an HDV cRNA, one that had been altered so
that yAg species did not occur. Thus, in the uninduced state,
low levels of HDV genome replication continued for at least 2
years, due to leaky expression of yAg mRNA for the uninduced
promoter, and without any deleterious effects on the host cell.
Furthermore, when higher levels of yAg were induced in the
cells, high levels of HDV RNAs were transcribed and
accumulated. Unexpectedly, this led to a cell-cycle arrest in
G1/G0 within 2 days, and to detachment and cell death within
6 days. Thus, RNA-editing with the appearance of large yAg
and down regulation of replication seems necessary for cell
survival.
In this system, expression of the yAg alone did not have a
cytopathic effect. This absence of a cytopathic effect is just as
others have reported for mice made transgenic for yAg-S or
yAg-L (Guilhot et al., 1994). In contrast, the situation where
HDV genomic replication is induced and cells die, may be a
model for replication-associated cytopathogenicity. It might
help explain how in vivo, at the peak of natural and
experimental acute infections, HDV replication can be so
pathogenic (Farci, 2003; Gowans and Bonino, 1993). In
chronic infection, virus production and pathogenicity are much
lower. Thus, genome replication in vivo is initially fast enough
that cells die before adequate levels of large yAg are produced
to suppress HDV RNA synthesis.
Virus structure and assembly
As mentioned earlier, HDV makes use of the three HBV
envelope proteins. These have a common carboxyl-terminus,
and they are referred to by their sizes as large, middle and
small, or L, M and S. Each protein exists with and without
a site-specific N-linked carbohydrate modification. HBV
particle assembly, even in the absence of HDV, is very
inefficient in that most of the assembled particles are empty
and do not contain the HBV nucleocapsid structure or
genome. The serum of an infected patient may contain 1000
to 1,000,000 empty particles for every one that contains the
viral nucleocapsid (Ganem, 1991). Most of the empty
particles are spheres and filaments, about 22 nm in diameter,
that are composed predominantly of the S protein. Only
when the L protein is also present can the nucleocapsid be
enveloped to produce infectious 40 nm particles. Further-
more, the unique amino-terminus of the L protein is needed
for these particles to be infectious. The M protein is a minor
component and is apparently not necessary either for
assembly or infectivity.
HDV assembly makes use of the excess production of
envelope proteins, and inserts the HDV genomic RNAs and
about 70 molecules of yAg into particles containing L, M and
S. The S protein is sufficient for particle assembly, but the
particles so produced are not infectious. As with the infectious
J.M. Taylor / Virology 344 (2006) 71–76 73HBV, the L protein is also needed for infectivity (Sureau et al.,
1993).
It would seem that HBV and HDV use very similar
mechanisms for virus attachment and entry. However, some
caution is needed since in neither case do we know the host
receptor(s). We also do not know the post-entry steps. An
additional complication is that infectious HDV can be assembled
from HBV proteins that are not carbohydrate modified, but this
is not true for HBV (Sureau et al., 2003).
No cryo-electron microscopy has yet been reported for HBV
or HDV particles.
RNAs
As represented in Fig. 1, The HDV RNA packaged into
virions is by definition, the genome. It is a small 1679 nucleotide
single-stranded RNA with a circular conformation. Both
theoretically and experimentally, this RNA can fold on itself,
using 74% intra-molecular base-pairing, to form an unbranched
rod-like structure (Kuo et al., 1988; Wang et al., 1986).
HDV genome replication is via RNA-directed RNA
synthesis. Unlike the helper virus, HBV, there are no DNA
intermediates (Chen et al., 1986). During HDV genome
replication, up to 300,000 copies of genomic RNA accumulate
per cell (Chen et al., 1986). Also detected, in about 10-fold
lower amounts is an exact complement of the genome, called
the antigenome (Chen et al., 1986). As indicated in Fig. 1, the
genome and antigenome each contain a single ribozyme
domain of about 85 nucleotides (Ferre-D’Amare et al., 1998;
Sharmeen et al., 1988). Crystal structures have now been
obtained for the genomic ribozyme both in the pre- and post-
cleaved states. Such findings show that a conformational
switch occurs as a consequence of cleavage and also clarify the
role of a divalent metal ion in the cleavage event (Ferre-
D’Amare et al., 1998; Ke et al., 2004).Fig. 1. The three HDV RNAs that accumulate during genome replication. The
genome and its exact complement, the antigenome, are 1679 nucleotide long
single-stranded RNA circles, each possessing a ribozyme, with cleavage sites
indicated by red circles. The antigenome also contains the open reading frame
for the yAg and a poly(A) signal, as indicated. However, the yAg is actually
translated from a 800-nucleotide mRNA, that has a 5V-cap and a 3V-poly(A) tail.A third HDV RNA, typically 500 times less abundant than
the genome, is of the same polarity as the antigenome. As
indicated in Fig. 1, this RNA is linear and only about 800
nucleotides in length. It has a 5Vcap structure and a 3V-poly(A)
tail consistent with its role as mRNA for the translation of the
yAg (Nie et al., 2004).
As with the mRNA transcribed from a DNA template, the
HDV mRNA arises via post-transcriptional processing. Near to
the site of poly(A) addition on the antigenomic RNA is a
poly(A) signal, AAUAAA, and other sequence features, just as
seen for the processing of host mRNAs. Mutation of the HDV
poly(A) signal interferes with the accumulation of the mRNA
(Nie et al., 2004).
Fig. 2 is a representation of the mechanism of genome
replication, with emphasis on RNA transcription and
processing.
There are other RNAs produced during HDV replication.
Less abundant than monomers of the genome and antigenome
are dimers and trimers (Chen et al., 1986). Also, using pulse-
labeling conditions, even higher order multimers can be
detected (Macnaughton and Lai, 2002a). Some of these are
considered to be largely processed down to linear monomers
by the HDV ribozymes, and further processed to circles,
possibly by a host RNA ligase activity (Reid and Lazinski,
2000).
Delta antigen(s)
Initiation of HDV genome replication absolutely requires
the presence of the 195 amino acid yAg species (Chao et al.,
1990). This protein has been ascribed several properties, some
of which could contribute to it being essential (Taylor, 2006).
In addition to its RNA-binding ability, which may or may not
be specific for the HDV rod-like structure (Chao et al., 1991),
there is also evidence that the protein can facilitate in vitro
elongation of RNA transcription by host RNA polymerase II
(Yamaguchi et al., 2001).
During HDV genome replication in the nucleus, some of the
new HDV RNAs get post-transcriptionaly edited by an enzyme
of the class known as adenosine deaminase acting on RNA, or
ADAR. The small form of ADAR-1, is considered to be the
specific enzyme that acts on HDV RNA (Wong and Lazinski,
2002). It changes adenosine to inosine. This change is
immortalized by subsequent rounds of RNA-directed RNA
synthesis, as adenosine to guanosine.
The site of one such editing change corresponds to an
adenosine in the middle of the UAG amber termination codon
for the small yAg. The new codon, UGG, is translated as
tryptophan, to produce a 19-amino acid longer form of yAg.
Unlike the small form, this large form does not support genome
replication and in fact, under certain conditions can be a
dominant negative inhibitor (Chao et al., 1990), although there
is some contrary opinion (Macnaughton and Lai, 2002b;
O’Malley and Lazinski, 2005). However, what is clear is that
the large form has a separate and an essential role in the HDV
life cycle. It is needed for the assembly of new particles using
the HBV envelope proteins (Chang et al., 1991).
Fig. 2. A model of HDV genome transcription and processing. The three RNAs of HDV, and their associated sequence features, are as indicated in Fig. 1. (1) The
genomic RNA acts as a template for the transcription of an antigenomic RNA. (2) This nascent RNA transcript has the same 5V-end as the mRNA (Gudima et al.,
2000). It subsequently undergoes 5V-capping and 3V-poly(A) processing. (3) The genomic RNA acts as a template for other antigenomic RNA transcripts, some of
which since they are transcribed from a circular RNA template can achieve greater than unit-length. (4) These are processed in an alternative fashion to step 2. They
undergo ribozyme cleavage to release unit-length linear antigenomes. (5) These in turn, fold into the rod-like structure and are ligated to produce new antigenomic
RNA circles. (6–8) As in steps 4–6, the new antigenomic RNA can act as template for the transcription and processing of new genomic RNAs.
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the large yAg, there is a unique cysteine located 4 amino acids
from the carboxyl-terminus. It acts as a site for isoprenylation
(Glenn et al., 1992) and this modification is essential for the
ability of the large yAg to support HDV assembly (Bordier et
al., 2003).
Various other post-translational modifications of the large
and small delta proteins have also been described. There is
evidence for phosphorylation (Chang et al., 1988; Mu et al.,
1999), methylation (Li et al., 2004) and acteylation (Mu et al.,
2004). Some of the modification sites have been mapped and
certain of the modifications may be relevant to the HDV life
cycle.
RNA polymerase requirements
Since HDV encodes no more than the delta protein(s),
genome replication requires host polymerase activity. Much
data support the interpretation that host RNA polymerase II,
which is normally a DNA-directed RNA polymerase, is
redirected to carry out HDV RNA-directed transcription.
This picture is not, however, without some complications, as
can be seen from a recent review by Lai (2005). It is agreed that
Pol II is involved in the transcription to produce both genomic
RNA and mRNA. However, some data have been interpreted
as evidence that a polymerase resistant to >100 micrograms/ml
of amanitin, thus like Pol I, is involved in transcription toproduce antigenomic RNA. This has led to a very complex
model of rolling-circle replication, with genomic RNA
sometimes acting as a template for pol II and mRNA and
other times acting as a template for another enzyme, to make
antigenomic RNA.
Template-switching and recombination
It is most likely that during normal HDV genome
replication, the RNA templates used most frequently are unit-
length circular RNAs. However, some of the intracellular HDV
RNAs, especially the precursors to circular monomers, are
likely to be linear RNAs. And, from experimental studies, there
is evidence that replication can be initiated from HDV RNA
templates that are linear (Gudima et al., 2004). This process
involves intra-molecular template-switching during transcrip-
tion, and sometimes is associated with small deletions of HDV
sequences and/or insertions of non-templated nucleotides
(Chang and Taylor, 2002). In another study, pairs of HDV
RNAs, each much less than unit-length but together represent-
ing at least one copy of the entire HDV sequence, were
transfected into cells and full-length replicating genomes were
reconstituted, presumably by inter-molecular template-switch-
ing (Gudima et al., 2005).
Given the data for template-switching by a host RNA
polymerase on an RNA template, it might also be expected that
inter-molecular recombination could occur during natural
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with two different genotypes of HDV (Wu et al., 1999) and
also in cells transfected with two RNAs of different genotype
(Wang and Chao, 2005).
Virus attachment and entry
Since HDV shares the envelope proteins of HBV, many labs
think that the two viruses would use a very similar, if not
identical, attachment and entry mechanism. There is evidence
that a unique region near the amino-terminus of the HBV L
protein is needed for entry by both viruses (Barrera et al.,
2005). Puzzlingly, when the N-linked carbohydrate modifica-
tion of L, M and S is removed, the assembled HBV is non-
infectious while HDV remains infectious (Sureau et al., 2003).
More studies are needed on the attachment and entry
mechanisms for both viruses. Certainly, a better understanding
of virus entry might lead to additional options for anti-viral
therapy, for example, as used in anti-HIV therapies (Kilby et
al., 1998).
Also missing are data on post-entry events. Does HDV (or
HBV) entry require an endocytic pathway? Is there a need for
acidification within an endosomal compartment? And, once
released, how does the viral ribonucleoprotein make its way to
the nucleus for transcription; is this transport mediated by
microtubules?
Viroid analogy
Among the small subviral agents that can infect plants is a
group of small single stranded non-coding RNAs that are
known as viroids (Flores et al., 2004; Tabler and Tsagris,
2004). As reviewed elsewhere, there are many similarities
between these viroids and HDV (Taylor, 1999). Such
similarities have and will continue to lead to interesting new
findings. For example, the search for the HDV ribozymes was
motivated by certain earlier viroid findings. Also, new studies
of HDV genome replication, as described earlier in the
manuscript, have to some extent made the replication of
HDV in cultured cells much more like that of a plant viroid
(Chang et al., 2005b).
Nevertheless, there are still major differences between the
viroids and HDV: (i) The viroids have much smaller genomes
(typically 200–450 nucleotides). (ii) The viroids do not encode
any protein. (iii) The viroids do not have any known helper
virus.
More data are needed for both the viroids and HDV to
explain what is unique about RNAs that are recognized and
copied by host RNA polymerase(s).
Conclusions and outlook
As a cause of infectious disease HDV is coming under
control, largely due to the preventative vaccination against
HBV. Also, the majority of cases of chronic HDV is largely
holdovers from pre-vaccination times, and as such, is
progressively decreasing in number.As a source of intriguing molecular biology and molecular
virology, HDV continues to be very special. The best examples
of this are its ribozymes, the essential ADAR-editing, and of
course, the RNA-directed RNA synthesis by a redirected host
RNA polymerase(s). The latter process is the one that needs
significant clarification and less controversy. We and others
have sought for an in vitro Pol II transcription system using
HDV RNAs. To date, all that has been reproducibly achieved is
modest 3V-end addition reactions (Beard et al., 1996; Filipovska
and Konarska, 2000; Gudima et al., 2000; Yamaguchi et al.,
2001).
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